Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

2019-07-04T21:27:37+00:00November 14th, 2016|Categories: Press Releases|Tags: , , , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE Basel - [...]